Mycostatin

Pruritus Vulvae, Trichomonas Vaginitis, Pruritus Ani + 13 more

Treatment

14 Active Studies for Mycostatin

What is Mycostatin

Nystatin

The Generic name of this drug

Treatment Summary

Nystatin is a medication used to treat fungal infections caused by certain types of yeast and fungi. It is derived from a strain of the bacteria Streptomyces noursei and is closely related to Amphotericin B. Nystatin is more effective than Amphotericin B, but is not suitable for systemic use due to toxicity. It is usually administered orally or topically and it is not absorbed into the body, so it only works on the surface of the skin, mucous membranes, or gastrointestinal tract.

Nystatin

is the brand name

image of different drug pills on a surface

Mycostatin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nystatin

Nystatin

1979

252

Effectiveness

How Mycostatin Affects Patients

Nystatin is an antifungal drug that can stop the growth and spread of certain kinds of fungi. It works by affecting the cell membrane surrounding the fungus. While it is generally very effective against _Candida albicans_, other types of _Candida_ may become resistant to it. Nystatin does not affect bacteria, protozoa, or viruses. It cannot be used to treat systemic infections, so it must be applied topically, orally, or in the gastrointestinal tract.

How Mycostatin works in the body

Nystatin works by creating pores in the cell walls of fungi. This increases the permeability of the cell wall, allowing the contents inside the cell to leak out, leading to disruption of how the cell works. Nystatin is able to target fungal cells more effectively than mammalian cells because it has a stronger bond to ergosterol, which is a sterol found in fungal cell walls, than cholesterol, which is found in mammalian cell walls.

When to interrupt dosage

The suggested dosage of Mycostatin is contingent upon the recognized condition, such as cutaneous candidiasis, Skin candida and corticosteroid-responsive dermatoses. The measure of dosage fluctuates, in light of the technique of conveyance (e.g. Insert or Insert - Vaginal) presented in the table beneath.

Condition

Dosage

Administration

Skin candida

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Anal candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Skin Diseases

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Oral

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Low; Birthweight

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Ani

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

cutaneous candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Urinary Tract Infection (UTI)

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candida albicans

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Vulvae

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Trichomonas Vaginitis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Invasive

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Yeast Infection

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Warnings

Mycostatin has one contraindication, so it should not be merged with the conditions found in the following table.

Mycostatin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nystatin may interact with Pulse Frequency

There are 20 known major drug interactions with Mycostatin.

Common Mycostatin Drug Interactions

Drug Name

Risk Level

Description

Revefenacin

Major

Nystatin may decrease the excretion rate of Revefenacin which could result in a higher serum level.

Ambrisentan

Minor

The excretion of Ambrisentan can be decreased when combined with Nystatin.

Asunaprevir

Minor

The excretion of Asunaprevir can be decreased when combined with Nystatin.

Atorvastatin

Minor

The excretion of Atorvastatin can be decreased when combined with Nystatin.

Atrasentan

Minor

The excretion of Atrasentan can be decreased when combined with Nystatin.

Mycostatin Toxicity & Overdose Risk

The lowest toxic dose of nystatin in rats is 10 g/kg. Taking too much nystatin can cause nausea and stomach pain, but no other serious side effects have been reported, even when doses of up to five million units are taken in one day.

Mycostatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Mycostatin?

39 active clinical trials are currently being conducted to examine the potential of Mycostatin to mitigate Urinary Tract Infection, Yeast Infection and Anal Itching.

Condition

Clinical Trials

Trial Phases

Pruritus Ani

0 Actively Recruiting

Candida albicans

0 Actively Recruiting

Skin candida

0 Actively Recruiting

Anal candidiasis

0 Actively Recruiting

Candidiasis, Invasive

4 Actively Recruiting

Phase 3, Not Applicable

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Candidiasis, Oral

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Low; Birthweight

2 Actively Recruiting

Not Applicable

Skin Diseases

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Candidiasis

0 Actively Recruiting

Candidiasis, Vulvovaginal

2 Actively Recruiting

Not Applicable, Phase 3

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Pruritus Vulvae

0 Actively Recruiting

Candidiasis, Vulvovaginal

0 Actively Recruiting

Mycostatin Reviews: What are patients saying about Mycostatin?

5

Patient Review

10/9/2008

Mycostatin for Thrush

This was easy to take and I didn't mind the taste. Most importantly, it worked great!

5

Patient Review

2/20/2011

Mycostatin for Stomach and Intestinal Infection caused by the Fungus Candida

This medication is effective, but I was told that I have to take it regularly in order to manage my candida. So far, no side effects and I feel really good after taking it!

4

Patient Review

10/24/2020

Mycostatin for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

I just started using Mycastatin. I find it very easy to use--the taste is not bad, slight bitterness that one can tolerate. I have not completed treatment yet so I cannot speak to its effectiveness; however, I will return and update this review once I am finished.

3.7

Patient Review

12/15/2007

Mycostatin for Thrush

The taste is really off-putting, but it works well enough that I can overlook it.

3.7

Patient Review

7/18/2012

Mycostatin for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

The taste is incredibly unpleasant, but it's worth it for the results.

Patient Q&A Section about mycostatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is mycostatin used for?

"This medication, Nystatin, is used to treat fungal infections of the mouth. It works by stopping the growth of fungus. Nystatin suspension should not be used, however, to treat fungal infections of the blood."

Answered by AI

Is nystatin and mycostatin the same?

"Nystatin is an antibiotic that is used to treat fungal infections. It is available as a cream or powder."

Answered by AI

How long does it take mycostatin to work?

"It is typically recommended to take nystatin liquid four times a day, approximately 30 minutes after eating or drinking. The medication usually begins to work after two days, though it is important to continue using it for two days after symptoms have improved."

Answered by AI

What is the generic name for mycostatin?

"brand names for Nystatin include Mycostatin, Nilstat, Nyamyc, Nystat Rx, Nystatin Systemic, Nystex, and Nystop."

Answered by AI

Clinical Trials for Mycostatin

Have you considered Mycostatin clinical trials?

We made a collection of clinical trials featuring Mycostatin, we think they might fit your search criteria.
Go to Trials
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Phase 4
Recruiting

University of Missouri

Kevin M Klifto, DO, PharmD

Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Antifungal Therapy Duration for Candidemia in Children

120 - 18
All Sexes
Philadelphia, PA

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

Recruiting
Has No Placebo

Children's Hospital of Philadelphia (+17 Sites)

Brian Fisher, DO

Image of Rush University Medical Center in Chicago, United States.

Menstrual Cups for Vaginal Infections

15 - 35
Female
Chicago, IL

HIV remains a global pandemic with 37 million infected. In western Kenya, 16% of women in the general population and 29% of the poorest women have HIV. The HIV and sexually transmitted infection (STI) epidemics overlap with broader reproductive health concerns. Menstrual hygiene management is a big problem in low- and middle-income countries and a lack of menstrual products negatively impacts women's work-life. This comes from cultural taboos, stigma, and discrimination, promoting secrecy around menstruation, high cost of menstrual products, use of traditional materials (e.g. rags, cotton wool, etc.) causing leakage and odor, and lack of water and safe hygiene facilities. Menstrual cups designed for use during sex may help women prevent Bacterial vaginosis (BV) and STIs through hygienic period practices, and may help them avoid bad practices in an attempt to maintain vaginal dryness. The goal of this interventional trial is to test the impact of menstrual cups on vaginal microbiome, BV, and STIs of poor women at high risk for STIs and HIV. We predict to see 25% less BV, our primary outcome, over one year. This trial aims to learn more about the safety of the intervention, and understand what is needed to fully implement the program.

Phase 2
Waitlist Available

Rush University Medical Center

Have you considered Mycostatin clinical trials?

We made a collection of clinical trials featuring Mycostatin, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Data Accountability + Doula Support for Maternal Health Disparities

12 - 99
Female
Chapel Hill, NC

This project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 39 prenatal practices across North Carolina. Practices have been randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for \~750-1,500 patients (up to 60,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.

Recruiting
Has No Placebo

University of North Carolina at Chapel Hill

Jennifer H Tang, MD, MSCR

Image of Houston Methodist Hospital - Texas Medical Center in Houston, United States.

Fosmanogepix for Candida Blood Infection

18+
All Sexes
Houston, TX

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

Phase 3
Recruiting

Houston Methodist Hospital - Texas Medical Center (+12 Sites)

Manuel Häckl, MD

Basilea Pharmaceutica